Clinical

Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide

Ajay S. Behl, PhD, Lorie A. Ellis, PhD, Dominic Pilon, MA, Yongling Xiao, PhD

Ajay S. Behl, PhD; Lorie A. Ellis, PhD; Dominic Pilon, MA; Yongling Xiao, PhD; Patrick Lefebvre, MA

Stakeholder Perspective

A First Step Toward Improving the Complex Approach to Metastatic Prostate Cancer Management

Gary M. Owens, MD

by Gary M. Owens, MD

Clinical, Original Research

The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data

Annlouise R. Assaf, PhD, Andrew G. Bushmakin, MS, Nina Joyce, PhD, Michael J. Louie, MD, MPH, MSc, Michael Flores, MPH, Margaret Moffatt, MPH

Annlouise R. Assaf, PhD; Andrew G. Bushmakin, MS; Nina Joyce, PhD; Michael J. Louie, MD, MPH, MSc; Michael Flores, MPH; Margaret Moffatt, MPH

Stakeholder Perspective

Hormone Therapy Remains Effective for Treating Menopausal Symptoms, May Save Overall Costs

JoAnn V. Pinkerton, MD, FACOG, NCMP

by JoAnn V. Pinkerton, MD, FACOG, NCMP

Clinical

The Medical and Economic Burden of Narcolepsy: Implications for Managed Care

Michael J. Thorpy, MB, ChB, George Hiller, RPh

Michael J. Thorpy, MB, ChB; George Hiller, RPh

Stakeholder Perspective

Improved Diagnosis and Treatment of Narcolepsy May Also Help to Reduce the Associated Costs

James T. Kenney, RPh, MBA

by James T. Kenney, RPh, MBA

Clinical, Original Research

Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas

Kelly F. Bell, PharmD, MSPhr, MS, Katherine Cappell, PhD, Michael Liang, MS, Amanda M. Kong, MPH

Kelly F. Bell, PharmD, MSPhr, MS; Katherine Cappell, PhD; Michael Liang, MS; Amanda M. Kong, MPH

Stakeholder Perspective

Real-World Studies in Diabetes Needed to Improve Medication Adherence and Persistence

Brian Caveney, MD, JD, MPH

by Brian Caveney, MD, JD, MPH

Clinical, Original Research

Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes

Kelvin Lingjet Tran, DO, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACE, FTOS

Kelvin Lingjet Tran, DO; Young In Park, DO; Shalin Pandya, DO; Navin John Muliyil, DO; Brandon David Jensen, DO; Kovin Huynh, DO; Quang T. Nguyen, DO, FACP, FACE, FTOS

Stakeholder Perspective

The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes

Raymond Plodkowski, MD

by Raymond A. Plodkowski, MD

Clinical, Original Research

Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea

Todd Williamson, PhD, MSc, Rajesh Kamalakar, MS, Augustina Ogbonnaya, MPH, Erin A. Zagadailov, PharmD, MS, Michael Eaddy, PharmD, PhD, Charlie Kreilick, MBA

Todd Williamson, MsC; Rajesh Kamalakar, MS; Augustina Ogbonnaya, MPH; Erin A. Zagadailov, PharmD, MS; Michael Eaddy, PharmD, PhD; Charlie Kreilick, MBA

Stakeholder Perspective

The Challenge of Rosacea Treatment

Atheer A. Kaddis, PharmD

by Atheer A. Kaddis, PharmD

Clinical

Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm

Jordan S. Orange, MD, PhD, Matt Johnson, BA, Barbara Lennert, RN, BSN, MAOM, Katarzyna Shields, PharmD, MBA, BCOP, BCPS, Michael Eaddy, PharmD, PhD

Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields, PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD

Stakeholder Perspective

A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy

Gary Branning, MBA

by Gary Branning, MBA

Clinical

Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy

Dominic Pilon, MA, Ajay S. Behl, PhD, Lorie A. Ellis, PhD, Marie-Noëlle Robitaille, MA, Patrick Lefebvre, MA, Nancy A. Dawson, MD

Dominic Pilon, MA; Ajay S. Behl, PhD; Lorie A. Ellis, PhD; Marie-Noëlle Robitaille, MA; Patrick Lefebvre, MA; Nancy A. Dawson, MD

Stakeholder Perspective

Role of Real-World Evidence in Clinical Decision-Making for the Management of Advanced Prostate Cancer

Brian Caveney, MD, JD, MPH

by Brian Caveney, MD, JD, MPH

Clinical, Original Research

Comparing Healthcare Utilization and Costs Among Medicaid-Insured Patients with Chronic Noncancer Pain with and without Opioid-Induced Constipation: A Retrospective Analysis

Tope Olufade, PhD, MPH, Amanda M. Kong, MPH, Nicole Princic, MS, Paul Juneau, MS, Rucha Kulkarni, MPH, Kui Zhang, MD, Catherine Datto, MD, MS

Tope Olufade, PhD, MPH; Amanda M. Kong, MPH; Nicole Princic, MS; Paul Juneau, MS; Rucha Kulkarni, MPH; Kui Zhang, MD; Catherine Datto, MD, MS

Stakeholder Perspective

The Opioid Epidemic: Healthcare Utilization and Cost Considerations

Jack E. Fincham, PhD, RPh

by Jack E. Fincham, PhD, RPh

Clinical, Original Research

Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population

Jill R. Davis, MS, Bingcao Wu, MS, David M. Kern, PhD, Ozgur Tunceli, PhD, Kathleen M. Fox, PhD, John Horton, MS, Randall F. Legg, PharmD, MBA, Frank Trudo, MD, MBA

Jill R. Davis, MS; Bingcao Wu, MS; David M. Kern, PhD; Ozgur Tunceli, PhD; Kathleen M. Fox, PhD; John Horton, MS; Randall F. Legg, PharmD, MBA; Frank Trudo, MD, MBA

Stakeholder Perspective

When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD

Michael F. Murphy, MD, PhD

by Michael F. Murphy, MD, PhD

Page 4 of 14
Results 31 - 40 of 133